Seema Dixit, DO
Neurology · Somerset, NJNPI 1144476417
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $50,822 of the $81,399 with a category attached, or 62.4%. 60 manufacturers reported payments, led by AbbVie at 48.0% of the total. Among neurology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,022 payments — averaging $40.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$39K
- Axsome Therapeutics, Inc.$9K
- UCB, Inc.$9K
- Novartis$3K
- Supernus Pharmaceuticals, Inc.$2K
- Biogen$2K
- plus $17K from 54 others
What the payments were for
- Consulting fees$2,5353%
- Speaking & faculty fees$50,82262%
- Travel & lodging$2360%
- Food & beverage$27,52234%
- Education$2840%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$33,862
- QULIPTA$10,196
- Symbravo$9,036
- Briviact$6,985
- OXTELLAR XR$1,500
- TYSABRI$300
- VNS Therapy$149
- AUBAGIO$130
- NOURIANZ$124
- ZEPOSIA$122
- NURTEC ODT$105
How this compares
$81,399 in reported general payments places this provider in the 95th percentile of 521 neurology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VumerityDiroximel Fumarate | 21 | $190,799 |
| Kesimpta PenOfatumumab | 15 | $146,749 |
| UbrelvyUbrogepant | 64 | $93,169 |
| EpidiolexCannabidiol (Cbd) | 23 | $87,125 |
| Nurtec OdtRimegepant Sulfate | 65 | $79,535 |
| Aimovig AutoinjectorErenumab-Aooe | 67 | $61,163 |
| Oxtellar XrOxcarbazepine | 34 | $59,174 |
| BriviactBrivaracetam | 35 | $58,045 |
| AptiomEslicarbazepine Acetate | 11 | $54,698 |
| QuliptaAtogepant | 42 | $50,577 |
| XcopriCenobamate | 37 | $41,246 |
| ValtocoDiazepam | 15 | $38,387 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 32 | $37,484 |
| KeppraLevetiracetam | 25 | $33,953 |
| Lamotrigine ErLamotrigine | 34 | $27,620 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenVumerity | $1,770 | $190,79921 claims |
| AbbVieUbrelvy, Qulipta, Botox | $39,076 | $159,589120 claims |
| PfizerNurtec Odt, Dilantin | $411 | $83,19178 claims |
| Supernus Pharmaceuticals, Inc.Oxtellar Xr | $2,132 | $59,17434 claims |
| UCB, Inc.Briviact | $8,592 | $58,04535 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $491 | $54,69811 claims |
| SK Life Science, Inc.Xcopri | $823 | $41,24637 claims |
| Neurelis, Inc.Valtoco | $507 | $38,38715 claims |
| MerckBelsomra | $52 | $11,56525 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $318 | $8,82513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 521 neurology providers in New Jersey.
Other neurology in Somerset
- Roger BeharSomerset$87K
- Stephanus BusonoSomerset$51K
- Steven BromleyAudubon$1.5M
- Mary Ann PiconeTeaneck$1.5M
- Fiona GuptaOradell$1.1M
- Matthew DavisMiddletown$567K
- Amos KatzEatontown$558K
- Monte PellmarFreehold$429K
- Marcie RabinSummit$387K
- Ashish KapoorBayonne$329K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.